



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. : 10/700,906 Confirmation No.: 1129
 Applicant : Benjamin OSHLACK et al.
 Filed : November 4, 2003
 Art Unit : 1615
 Examiner : Humera N. SHEIKH
 For : **TAMPER-RESISTANT ORAL OPIOID
AGONIST FORMULATIONS**
 Attorney Docket No. : 200.1133CONS5
 Customer No. : 23280

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

September 3, 2008

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.56**

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, and further to the Information Disclosure Statement filed on November 4, 2003, Applicants hereby make of record the documents cited on the accompanying Form PTO-1449 (2 pages) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. 1.98(a)(2), a copy of the document cited in the FOREIGN PATENT DOCUMENTS section of accompanying Form PTO-1449 is enclosed. If it is determined that a copy of the cited documents is missing, the Examiner is respectfully requested to contact the undersigned so that a duplicate copy may be forwarded.

Applicants also submit herewith for the Examiner's consideration copies of the Office Actions issued in connection with the following applications which are assigned to the owner of the instant application:

- 1) U.S. Patent Application Serial No. 09/781,081, filed February 8, 2001, now U.S. Patent No. 6,696,088;
- 2) U.S. Patent Application Serial No. 10/689,866, filed October 21, 2003;
- 3) U.S. Patent Application Serial No. 10/701,041, filed November 4, 2003;
- 4) U.S. Patent Application Serial No. 10/700,893, filed November 4, 2003; and
- 5) U.S. Patent Application Serial No. 70/700,861, filed November 4, 2003.

It is respectfully requested that the information in these Office Actions and the documents cited on the accompanying Form PTO-1449 (2 pages) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), “[b]efore the mailing of a first Office action after the filing of a request for continued examination under § 1.114.” Accordingly, it is believed that no fee is due. If it is determined that any additional fee is due in connection with the filing of this Information Disclosure Statement, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Oleg Joselevich
Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940